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Abstract: Breast cancer is the leading cause of death among women worldwide. Over the years, 
oxidative stress has been linked to the onset and progression of cancer. In addition to the classical 
histological classification, breast carcinomas are classified into phenotypes according to hormone 
receptors (estrogen receptor—RE—/progesterone receptor—PR) and growth factor receptor (hu-
man epidermal growth factor receptor—HER2) expression. Luminal tumors (ER/PR-positive/HER2-
negative) are present in older patients with a better outcome. However, patients with HER2-positive 
or triple-negative breast cancer (TNBC) (ER/PR/HER2-negative) subtypes still represent highly ag-
gressive behavior, metastasis, poor prognosis, and drug resistance. Therefore, new alternative ther-
apies have become an urgent clinical need. In recent years, anticancer agents based on natural prod-
ucts have been receiving huge interest. In particular, carotenoids are natural compounds present in 
fruits and vegetables, but algae, bacteria, and archaea also produce them. The antioxidant properties 
of carotenoids have been studied during the last years due to their potential in preventing and treat-
ing multiple diseases, including cancer. Although the effect of carotenoids on breast cancer during 
in vitro and in vivo studies is promising, clinical trials are still inconclusive. The haloarchaeal carot-
enoid bacterioruberin holds great promise to the future of biomedicine due to its particular struc-
ture, and antioxidant activity. However, much work remains to be performed to draw firm conclu-
sions. This review summarizes the current knowledge on pre-clinical and clinical analysis on the 
use of carotenoids as chemopreventive and chemotherapeutic agents in breast cancer, highlighting 
the most recent results regarding the use of bacterioruberin from haloarchaea. 
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1. Introduction 
Reactive nitrogen (RNS) and oxygen (ROS) species are metabolic by-products gener-
ated by all biological systems. More specifically, superoxide radicals (O2•−), hydroxyl rad-
icals (•OH), singlet oxygen (1O2), and hydrogen peroxide (H2O2) are the most frequent 
ROS produced [1]. An equilibrium between ROS production and metabolization is re-
quired for most biological processes to function. When there is an imbalance in favor of 
ROS production, most biomolecules and cellular structures are negatively affected. Over 
the years, it has been repeatedly reported how oxidative stress can be one of the causes 
behind the onset and progression of many pathologies, including cancer, heart disease, or 
diabetes [2]. 
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Cancer is considered a multi-stage process in which genetic and epigenetic altera-
tions accumulate. These alterations produce the dominant activation of different onco-
genes and the inactivation of tumor suppressor genes, ultimately leading to the malignant 
transformation of healthy cells [3,4]. Although a small percentage of human cancers are 
linked to genetic inheritance, the vast majority are caused by infections, chemical exposure 
and factors regarding lifestyle, such as smoking, diet, and UV radiation [5]. Over the last 
decades, there has been a constant rise in research focused on oxidative stress, inflamma-
tion, and cancer [6,7]. Antioxidants can counteract oxidative stress, thus helping prevent 
and delay in the development of this neoplasia [8].  
Over the last years, there has been an increasing interest in microbes as natural 
sources for the production of carotenoids due to their remarkable antioxidant properties. 
The use of microbial species can be very advantageous since they produce high rates of 
carotenoids which can be isolated using environmentally friendly approaches; thus re-
ducing the cost and the environmental impact compared to the chemical synthesis of ca-
rotenoids [9,10]. Extremophilic microorganisms that inhabit solar salterns (halophilic mi-
crobes) are usually exposed to high levels of oxidative stress as a consequence of high 
solar radiation or high temperatures (up to 50 °C in summer). In response to this stress, 
they have developed several molecular adaptations, such as the synthesis of carotenoids, 
which are very active against ROS [11]. Thus, it was described that extreme halophilic 
microorganisms belonging to Archaea domain (haloarchaea) can produce carotenoids, 
particularly rare carotenoids containing 50 carbon units, being bacterioruberin the most 
abundant. Haloarchaeal C50 carotenoids have caught the attention of many researchers 
due to their particular structures, which would provide them with higher scavenger ac-
tivity than their C40 counterparts [12]. However, the actual beneficial effect of these natural 
antioxidants on human health is yet to be determined. 
In this review, we summarize the recent advance in the use of carotenoids in prevent-
ing and treating breast cancer, highlighting the potential of bacterioruberin.  
2. Breast Cancer Epidemiology 
Breast cancer is one of the most frequent malignancies worldwide, representing 
11.7% of all cancers [13]. This neoplasia is considered genetically and clinically heteroge-
neous, including various subtypes, with distinct histopathological patterns and molecular 
characteristics, resulting in different responses to therapies and prognosis [14–16]. Alt-
hough mortality risk decreases every year in developed countries, breast cancer incidence 
increases [13]. Even though there are differences between countries, it is still the leading 
cause of death in women between 20 and 50 years [17]. However, only less than 10% of 
breast cancers are thought to be hereditary. Most cases are associated with lifestyle 
choices, dietary habits, and environmental and reproductive factors that increase the risk 
of breast cancer and other chronic diseases [18,19]. Significant efforts are currently being 
made to develop new and improved detection strategies, therapeutic targets, and better 
treatments. About two decades ago, Perou and colleagues proposed an “intrinsic genetic 
signature” made up of 496 genes [14]. This genetic signature allowed the classification of 
breast cancer into four molecular subtypes, representing different biological and clinical 
entities [14]. Subsequent studies have made it possible to redefine these molecular sub-
types [20–22]. However, despite different nomenclatures and molecular subtypes, breast 
cancer is routinely classified by immunohistochemical methods into four well-differenti-
ated phenotypes based on the expression of estrogen and progesterone receptors (RE/RP) 
and human epidermal growth factor 2 (HER2): Luminal A, Luminal B, HER2-pure, and 
triple negative (TNBC), the latter being the most heterogeneous [23]: 
• Luminal A tumors represent 50–60% of all breast cancer cases. These tumors show 
ER and PR expression, but HER2 is negative. In general, patients have a good prog-
nosis since these tumors have low histological grade and proliferation rates [24];  
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• Luminal B tumors are also ER/PR positive, and they can present HER2 overexpres-
sion/amplification or not, with higher proliferation rates than Luminal A tumors. In 
addition, these tumors progress to some extent faster than Luminal A tumors [25]; 
• HER2-enriched tumors express neither of the two hormone receptors (HR), and they 
are HER2-positive. Generally, this molecular subtype is associated with a high histo-
logical grade, and, from a clinical point of view, it is characterized by having a poor 
prognosis. Nevertheless, therapies targeting HER2 proteins are usually successful 
[26]; 
• TNBC express neither HR nor HER2, and, therefore, they have no specific target for 
treatment. However, clinically, they behave more aggressively, with higher metasta-
sis rates to the brain and lung [27]. 
Representative cell lines for each defined breast cancer subtype are available for in 
vitro assays so that the distinctive effect of antitumor agents can be explored (Figure 1). 
T47-D (Figure 1A) and MCF-7 (Figure 1B) cell lines present an ER/PR+ phenotype, thus 
being examples of Luminal A subtype. BT-474 presents Luminal B features such as HER2 
overexpression, as well as ER/PR expression (Figure 1C). HER2-enriched subtype can be 
studied thanks to SK-BR-3 (Figure 1D) and MDA-MB-453 cell lines. Among triple negative 
tumors, we can distinguish between triple negative/Basal-like and triple negative/Claudin 
low depending on gene expression characteristics [28], with MDA-MB-468 (Figure 1E) and 
MDA-MB-231 (Figure 1F) as their representative cell lines, respectively. 
 
Figure 1. Breast cancer cell lines. (A) T47-D and (B) MCF-7 cell lines are representative of luminal A (ER/PR+) phenotypes. 
(C) BT-474 cell line represents the Luminal B/HER2+ tumors. (D) SK-BR-3 cell line is characterized by the lack of ER and 
PR expression but it overexpresses the HER2/c-erb-2 gene, thus representing HER2-enriched subtype. (E) MDA-MB-468 
cell line belongs to the triple negative/Basal-like (ER/PR and HER2 negative) phenotype. (F) MDA-MB-231 cell line consti-
tutes the triple negative/Claudin-low subtype. (Image credit: Yoel Genaro Montoyo-Pujol). Scale bars of 100 µm are in-
cluded in each micrograph.  
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About 60–70% of breast cancers are of luminal subtype, therefore hormone-sensitive 
and responsive to endocrine therapy and relatively good prognosis [29]. However, HER2-
positivity has been more frequently reported in HR-negative than HR-positive cancers, 
correlated with aggressive clinical behavior and poor prognosis. Despite the fact that no-
vel HER2-targeted therapies have dramatically improved the outcome in HR-nega-
tive/HER2-positive patients, drug-related side effects are yet major obstacles ahead [30].  
TNBC represents a specific subtype accounting for approximately 15–20% of breast 
cancers, characterized by negative ER/PR/HER2 expression. Patients show a highly ag-
gressive clinical outcome, tending to earlier relapses and frequent metastasis to the brain 
and lungs, and, therefore, poorer survival compared with other subtypes [31].  
In addition, neoplastic transformation results from the dysfunction of signal trans-
duction networks that regulate molecular communications and cellular processes. Among 
them, several signaling pathways have been described to be deregulated in breast carci-
noma, including the PI3K/Akt/mTOR pathway, Notch pathway, Hedgehog pathway, 
ERK/MAPK pathway, NF-kB pathway, FOXO1/JAK/STAT pathway, TP53 pathway, 
Wnt/β-catenin, as well as apoptotic and cell cycle pathways. These networks are highly 
adaptable and dynamic [32]. 
Furthermore, the results of recent retrospective and prospective clinical studies have 
shown that the molecular classification of breast cancer subtypes and the mechanisms of 
interaction between tumors and immune cells of different subtypes are significant for pre-
dicting therapeutic response and prognosis and developing individualized treatment [33]. 
Therefore, despite the overall successes in breast cancer therapy, which have improved 
the prognosis, significant challenges exist in managing and treating patients who recur, 
develop resistance, or show no responsiveness since they do not have therapeutic targets. 
Hence, it is urgent to investigate novel and more effective agents without side effects in 
addition to conventional chemotherapy. In this regard, carotenoids are attracting enor-
mous attention as promising drug candidates in breast cancer treatment. 
3. The Role of Oxidative Stress in Cancer 
Cancer in humans is a multifactorial pathology triggered by endogenous and exoge-
nous factors [34]. During the development of tumors, nutrient and oxygen concentrations 
change due to the dynamics of the vasculature. Combining these changes with tissue re-
modeling events shapes the tumor metabolic landscape, complexly involving both cell-
autonomous and non-cell-autonomous mechanisms [35,36]. It is not entirely clear how 
tumors cope with low nutrient and oxygen concentrations. When such deficits are sensed, 
suitable cellular responses are elicited, and new vasculature is ultimately established [37]. 
Changes in mitochondrial metabolism mediate early responses to sharp drops in oxygen 
tension and, in particular, the generation of reactive oxygen species (ROS) [38]. 
Although ROS are essential in maintaining the equilibrium between pro-oxidant and 
antioxidant molecules, an excessive amount of these molecules negatively affects the 
structure and function of most biomolecules [39]. Oxidative stress can cause DNA damage 
and mutations, hydrolyzation of DNA bases, oncogene activation, and chromosomal ab-
normalities [40]. These alterations can promote tumor progression since they modify the 
transcriptomic profile, thus leading to impaired cell growth [41]. CpG islands can also be 
affected, causing loss of epigenetic information [42]. Furthermore, the oxidation of DNA 
by ROS releases 8-hydroxy-2-deoxyguanosine, which can generate DNA mutations 
[43,44]. Other possible DNA modifications include strand breaks, DNA-protein cross-
links, base-free sites, and base and sugar lesions [45]. However, not only DNA is affected 
by oxidative stress. ROS can oxidize lipoproteins, and the polyunsaturated lipids in the 
cell membrane due to lipid peroxidation [46]. In fact, lipid peroxidation is a radical chain 
reaction that generates cytotoxic and mutagenic compounds, such as malondialdehyde 
[46]. In addition, protein structure might be damaged, leading to conformational changes 
or loss of function [47]. 
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ROS release during oxidative stress can be provoked by endogenous or exogenous 
stimuli [48]. In addition, countless enzymatic reactions in the cell are endogenous sources 
of oxidative stress as part of the metabolism [49]. For example, the radical O2•− is released 
by lipoxygenases, cyclooxygenases, and inflammatory cells during cellular respiration 
[50]. However, it is well established that also lifestyle strongly influences the levels of ox-
idative stress, thus increasing the risk of cancer development [51,52].  
Several oncogenic pathways are activated by high levels of ROS [53], such as the 
phosphoinositide 3-kinases pathway (PI3K). Phosphatase and tensin homolog (PTEN) can 
be inactivated by the oxidation of its regulatory Cys 124 residue due to the interaction 
with ROS, such as H2O2[54]. Furthermore, the formation of a disulfide bond between 
Cys124 and Cys71 leads to PTEN inactivation, thus inducing the hyperactivation of the 
PI3K signaling pathway [55,56]. In consequence, protein kinase B (AKT) is constantly up-
regulated, which results in the continuous expression of genes involved in the activation 
of the cell cycle, for example, cyclin-dependent kinase 1 (CDK1) [57]. During the initiation 
of a tumor, blood vessels are poorly developed, creating a hypoxic environment [58]. Hy-
poxia causes an alteration in the mitochondrial electron transport chain, which releases 
more ROS that contributes to the activation of hypoxia-inducing factor-1 (HIF-1) [59]. 
More specifically, prolyl hydroxylase domain (PHD), a HIF-1 inhibitor, is inactivated in 
ROS. HIF-1 is a transcription factor that induces the expression of vascular endothelial 
growth factor (VEGF) and aerobic glycolysis [60]. In addition, tumor proliferation is en-
hanced due to the HIF-1-dependent activation of the c-Myc pathway [61]. High ROS levels 
also contribute to the invasiveness of a tumor due to the activity of transforming growth 
factor beta-1 (TGFß1) [62]. TGFß1 induces the epithelial-mesenchymal transition (EMT) 
and the secretion of various invasiveness biomarkers, such as VEGF and interleukin 6 [63]. 
Furthermore, ROS activates matrix metalloproteinase (MMP) synthesis via Ras and 
MAPK signaling pathways or via NF-kB [64].  
Tumor cells can tolerate higher ROS levels than normal cells since they modulate the 
redox environment and use it to proliferate. Nevertheless, if a certain threshold of ROS 
levels is surpassed, even tumor cells cannot adapt, and, therefore, cell death pathways are 
activated [53].  
In particular, high levels of oxidative stress in breast cancer have been reported in the 
literature since breast cancer cells also present an enhanced ROS production and low cat-
alase activity. ER-positive tumors show higher levels of 8-hydroxy-2-deoxyguanosine 
than ER-negative [65]. Gene alterations in breast cancer are thought to be caused by ROS 
released by estrogen-induced oxidative stress. Breast tissue is sensitive to DNA damage 
by natural and synthetic estrogens [66,67]. It has been repeatedly stated that elevated ROS 
levels induce tumor initiation. As a consequence, cancer cells with a robust antioxidant 
capacity may experience selection pressure. However, cancer cells also present higher 
ROS concentrations than normal cells. Based on this premise, it has been suggested that 
cancer cells could be more sensitive than normal cells to a further increase in ROS levels, 
thus selectively targeting neoplastic cells [22,45]. In theory, these additional ROS would 
spare their effect on normal cells because ROS would be present at physiological levels 
[68]. However, there are still no solid results from pre-clinical and clinical studies to sup-
port this theory, and much work remains to be performed to draw firm conclusions.  
The use of antioxidants holds promises since they would exert their antioxidant ac-
tivity on non-tumoral cells, whereas pro-oxidant activity would affect cancer cells. This 
approach is based on the pro-oxidant activity that many antioxidants presents, which will 
be further discussed in Section 5.1. However, pro-oxidant therapy is an emerging concept 
that has not been deeply explored yet. In addition, many breast cancer chemotherapeutic 
drugs, such as taxanes and anthracyclines, can induce oxidative stress in the brain and 
blood as a side effect [69]. 
For this reason, the administration of exogenous antioxidants has been studied dur-
ing the last years to counteract the detrimental effects of neoplastic treatment in healthy 
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tissues to prevent neurotoxicity [70]. Particularly, phytochemicals such as some carote-
noids, terpenoids, and polyphenols can modulate various oncogenic pathways. Therefore, 
they are being investigated as potential therapeutics [71].  
4. Antioxidants as a Defense Mechanism against Oxidative Stress 
Antioxidants are molecules that can prevent or slow damage to cells caused by free 
radicals, which are unstable molecules produced during metabolic reactions, not only un-
der “standard metabolic conditions” but also as a response to stressful environmental pa-
rameters or other pressures. They are sometimes called“free-radical scavengers”. From a 
functional point of view, antioxidants prevent or delay the oxidation of other molecules 
through the donation of hydrogen atoms or electrons. They are essential in the protection 
of the cells against free radicals like reactive oxygen species (ROS) and reactive nitrogen 
species (RNS), and, therefore, against oxidative stress [72].  
Antioxidants can be classified into several groups based on their role, chemical com-
position, etc. The most used classification establishes two broad divisions, depending on 
whether they are soluble in water (hydrophilic) or lipids (lipophilic). Water-soluble anti-
oxidants react with oxidants in the cell cytosol and the blood plasma, while lipid-soluble 
antioxidants protect cell membranes from lipid peroxidation [73].  
Cells can use several defense mechanisms against ROS and RNS, which work to-
gether to scavenge free radicals. There are endogenous and exogenous antioxidants, the 
latter being synthetic or natural [74]. Cells synthesize some molecules showing antioxi-
dant activity, such as glutathione, alpha-lipoic acid, coenzyme Q, ferritin, uric acid, bili-
rubin, metallothionein, L-carnitine, and small proteins such as thioredoxins (TRX). In ad-
dition, they act as an efficient reducing agent, scavenging reactive oxygen species and 
maintaining other proteins in their reduced state [75]. However, among the endogenous 
antioxidant repertoire of cells, it is worth highlighting the activity of some enzymes com-
monly named “antioxidant enzymes”[76]. A few of these enzymes are following listed:  
- Superoxide dismutase (SOD): catalyze the breakdown of the superoxide anion into 
oxygen and hydrogen peroxide [77]; 
- Catalase (CAT): catalyze the conversion of hydrogen peroxide to water and oxygen, 
using either an iron or manganese cofactor[78]; 
- Peroxiredoxins (PRXs): peroxidases that catalyze the reduction in hydrogen perox-
ide, organic hydroperoxides, as well as peroxynitrite [79]; 
- Glutathione peroxidases (GPXs): these are enzymes involved in a more complex 
pathway termed “glutathione system”, which includes glutathione, glutathione re-
ductase, glutathione peroxidases, and glutathione S-transferases. Within this series 
of reactions, glutathione peroxidase catalyzes the breakdown of hydrogen peroxide 
and organic hydroperoxides [80]. 
Based on the analyzed literature focused on antioxidant enzymes and cancer, the fol-
lowing features can be highlighted: (i) the activity of antioxidant enzymes is important for 
diagnosing neoplastic diseases such as non-small-cell lung cancer, bladder cancer, ovarian 
cancer, and colon cancer; (ii) non-small-cell lung cancer is usually characterized by de-
creased SOD and CAT activity and increased glutathione GST activity. Lowered SOD, 
CAT, and GPx activity are characteristic of bladder cancer. XOR, CAT, SOD, and GPx 
expression is decreased in patients with ovarian cancer. Colorectal cancer is characterized 
by increased MnSOD expression (in vitro studies) and SOD expression while CAT, GPx, 
and GR are decreased (in vivo study); and finally, (iii) SOD, CAT, and XOR are proposed 
as prognostic markers in cancer of the lung, bladder, ovarian, and colon [81]. Moreover, 
antioxidants can also be chemically synthesized, such as N-acetyl cysteine (NAC), py-
ruvate, selenium, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), and 
propyl gallate [82]. Some of these synthetic compounds have been tested in neoplastic 
cells reporting radioprotection, protection against acute toxicity of chemicals, antimuta-
genic activity, and antitumorigenic action [83]. However, BHT and BHA are not exempt 
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from controversy since contradictory data involves their beneficial effects and their po-
tentially harmful effects on human health [84]. The concerns regarding their biosafety are 
based on several studies reporting endocrine-disrupting effects [85], reproductive toxicity 
[86], and carcinogenity [87]. The controversy encourages re-evaluating the use of these 
synthetic antioxidants and exploring already known and new naturally derived antioxi-
dants that may benefit human health. 
Natural antioxidants are incorporated through the diet, including vitamins and ca-
rotenoids. Regarding vitamins, Vitamins C, E, and A show significant antioxidant activi-
ties. Vitamin C, also named ascorbic acid, is a redox catalyst that can reduce, and thereby 
neutralize ROS, such as hydrogen peroxide. Vitamin A is not a powerful antioxidant itself, 
but it has been reported that it plays a key role in inhibiting hepatic stellate cells (an effec-
tor of hepatocellular carcinoma) activation via suppressing thioredoxin-interacting pro-
tein and reducing oxidative stress levels. Finally, vitamin E (liposoluble) protects mem-
branes from oxidation by reacting with lipid radicals produced in the lipid peroxidation 
chain reaction [88,89]. 
In recent decades, the relevance of antioxidants in various biological processes such 
as aging, cancer, and inflammation has been reported [71,90–92]. Different approaches 
have been assessed, from prevention to treatment of several pathologies. Antioxidants 
could also help reduce the side effects of the oxidative stress generated by chemo and 
radiotherapy [93,94]. Among all antioxidants, carotenoids, many of which have been iden-
tified and extracted from marine microorganisms [10,12,95], have attracted a lot of atten-
tion due to their remarkable antioxidant properties and their potential as anticancer and 
immunomodulatory agents. 
5. Carotenoids 
Carotenoids are isoprenoid polyenes displaying lipophilic properties. In nature, they 
are pigments ranging from yellow to red which can be found in plants, algae, microor-
ganisms, and some animals [96,97]. There are more than 750 different carotenoid struc-
tures identified [98]. Carotenoids can be classified into two main groups: carotenes and 
xanthophylls. On the one hand, carotenes, such as β-carotene, have a chemical structure 
composed uniquely of carbon and hydrogen and are all vitamin A precursors (Figure 2A). 
On the other hand, xanthophylls present at least one oxygen group in their hydro-
carbon chain (Figure 2B) [99]. In contrast, they cannot act as precursors for vitamin A. 
Since carotenoids are composed of isoprenoid units, they usually contain numerous con-
jugated double bonds in their structure. This characteristic, combined with cyclic end 
groups in some cases, generates a series of stereoisomers that differ in their chemical and 
physical properties, such as solubility, stability, and light absorption [100]. When two 
parts of the structure linked by a double bond are on opposite sides of the plane, the ca-
rotenoid is in E-configuration. On the contrary, if both parts are on the same side of the 
plane it is called Z-configuration [101]. 
Fruits and vegetables contain many carotenoids, including α-carotene, β-carotene, 
lycopene, lutein, and zeaxanthin, among others [100]. Carotenoids are very well known 
for their remarkable antioxidant properties [102]. However, their relevance is not only 
subject to their ROS scavenging capacity. They can inhibit tumor growth and invasiveness 
and are apoptosis inducers, as it will be further discussed in Section 6 with the example 
of breast cancer [103]. Carotenoids can also modulate gene expression and possess anti-
inflammatory and immunomodulatory activities [104] (Figure 3). The anti-inflammation 
mechanisms of carotenoids include targeting inflammatory biomarkers, such as chemo-
kines and cytokines, a acute-phase proteins. Carotenoids can also promote PI3K/Akt and 
nuclear factor erythroid 2-like 2 (Nrf2) signaling pathways [105]. In addition, they can 
inhibit NF-kB, p38 MAPK, and JAK-2/STAT-3 signaling pathways, which are also related 
to tumorigenesis. Some carotenoids, such as astaxanthin, prevent neuronal death by reg-
ulating the Wnt/β-catenin signaling pathway and inducing angiogenesis [106]. However, 
in the case of tumor cells, carotenoids avoid the development of blood vessels, exerting 
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an anti-angiogenic activity [107,108]. Anti-adiposity activity has also been reported for 
some carotenoids, such as cantaxanthin, through the differentiation of adipose cells [109]. 
Carotenoids have been reported to induce the proliferation of immunocompetent cells 
and might boost host resistance to pathogens. For example, astaxanthin positively influ-
enced the intracellular calcium concentration and enhanced the capacity of neutrophils to 
eliminate microbes [102]. Furthermore, carotenoids can also increase gap junction for-




Figure 2. Examples of chemical 2D structures of carotenoids: (A) a carotenoid: cis-β,β-carotene (CID: 
5927317) and (B) a xanthophyll: all-trans-lutein (CID: 6433159). The oxygen group is highlighted in 
red. Chemical 2D structures obtained from PubChem (NIH). 
 
Figure 3. Biological properties of carotenoids. Although they are mainly known by their antioxidant 
activity, carotenoids can exert various effects on cells. 
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5.1. Antioxidants or Pro-oxidants? 
Carotenoids’ antioxidant activity is attributed to their double-bonded structure and 
their ability to delocalised unpaired electrons [111]. As a result, carotenoids are capable of 
quenching free radicals, such as superoxide (O2•−), hydroxyl (•OH), and peroxyl (ROO•) 
radicals. Carotenoids can also prevent lipid damage from peroxidation [112]. However, 
recent studies have provided evidence on the pro-oxidant activity of carotenoids under 
certain conditions. As a consequence of this pro-oxidant potential, the concentration of 
ROS might increase. Nevertheless, this property does not disregard the protective role of 
carotenoids. Still, the conditions determining the antioxidant and pro-oxidant activity 
must be clarified to ensure the goal [113]. Whether a carotenoid shows pro-oxidant or 
antioxidant properties depends mainly on the partial pressure of dioxygen (pO2) and the 
carotenoid concentration [41]. When pO2 is high, a carotenoid radical is generated (Car•), 
reacting with O2 releasing a carotenoid-peroxyl radical (Car-OO•). This compound can 
exert pro-oxidant activity through the oxidation of unsaturated lipids [114]. In conclusion, 
carotenoids usually exhibit antioxidant activity in the presence of low pO2 whereas, anti-
oxidant behavior is lost or becomes pro-oxidant when pO2 is high [115]. Elevated concen-
trations of a carotenoid also give rise to pro-oxidant behavior [41]. When the amount of 
oxidized anti-oxidant surpass certain levels, the pro-oxidant activity becomes more plau-
sible, leading to an increase in lipid peroxidation and modulating redox-sensitive genes 
and transcription factors [116,117]. In addition, each type of tumor presents a particular 
redox status which may influence how the carotenoid interacts with ROS [118]. However, 
pro-oxidant activity has proven to be helpful in the treatment of some tumor cells. 
6. Breast Cancer and Carotenoids 
Among the several lifestyle factors that might contribute to cancer development, di-
etary habits are one of the key ones [119]. However, antioxidant compounds, such as ca-
rotenoids, present naturally in food are promising chemopreventive agents [120,121] and 
have chemotherapeutical properties [122,123]. Several epidemiological studies have re-
vealed how the intake of fruit and vegetables, and more specifically of the carotenoids 
absorbed from these foods, correlates to a reduced incidence of different types of tumors 
[124–126]. Furthermore, carotenoids have been frequently reported to suppress the onset 
and progression of cancer by different mechanisms [102]. In addition, they are capable of 
counteracting other forms of cellular stress by modulating signaling pathways [127]. 
Therefore, carotenoids alone or in combination with conventional anticancer drugs might 
be a promising therapeutic strategy in the treatment of this pathology. Several chemother-
apeutic drugs, such as alkylating agents and platinum-based compounds, release free rad-
icals while exerting their cytotoxic activity [128]. Free radicals are partially responsible for 
tissue and organ injuries, such as cardiotoxicity, nephrotoxicity, and DNA damage. Alt-
hough endogenous antioxidants contribute to restoring oxidative balance, these natural 
pigments can also quench ROS activity. For this reason, carotenoids can alleviate the side 
effects of chemotherapy by protecting healthy tissues with their antioxidant activity 
[103,129]. The supplementation of carotenoids for cancer prevention is based on several 
mechanisms, including a role in cell cycle progression, the Wnt/β-catenin signaling path-
way, and the modulation of inflammatory cytokines [130–132]. 
6.1. In Vitro and In Vivo Studies 
Several carotenoids have shown antitumor activity in in vitro and in vivo assays. 
Lycopene delayed insulin-like growth factor 1 (IGF-1)-induced cell cycle progressionand 
apoptosis [133,134] in the MCF-7 breast cancer cell line. Lycopene and β-carotene were 
confirmed to induce cell cycle arrest and apoptosis in MCF-7, MDA-MB-231, and MDA-
MB-235 cell lines [135]. Although lycopene and β-carotene are classified into different 
groups, they have many structural similarities that suggest that lycopene could activate 
retinoid-like receptors. The activation of these nuclear receptors leads to the transcription 
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of several target genes, among which we would like to highlight RARβ given that it is a 
tumor suppressor gene. It is worth mentioning that most breast cancer tumors and breast 
cancer cell lines present low levels of RARβ receptor expression, thus potentially serving 
as a biomarker. Carotenes can work as precursors of (all-trans)-retinoic acid, which acts as 
ligand for RAR. The mechanism of action of β-carotene might be involved with retinoic 
acid metabolism and the transcriptional activation of antiproliferative and pro-apoptotic 
genes. Another signaling pathway involved in regulating the activity of breast cancer stem 
cells is PI3K/Akt, since Akt downregulates glycogen synthetase kinase 3β (GSK3β) by 
phosphorylation in the Ser9 residue, thus stabilizing β-catenin. Wnt/β-catenin signaling 
pathway plays a role in modulating stem cell self-renewal, differentiation, and cell prolif-
eration [136]. Crocin and crocetin can negatively impact the viability and the ability of 
invasion of triple-negative breast cancer cells (4T1) through the Wnt/β -catenin pathway 
[137]. β-carotene also inhibited the proliferation of MCF-7 cells by decreasing the expres-
sion of the anti-apoptotic proteins Bcl-2 and PARP and the survival protein NF-kB. It also 
downregulated Akt and ERK1/2, and, in consequence, there was a lower expression of 
superoxide dismutase-2 [122]. 
Recent studies have reported how lutein can induce cell death in the MCF-7 cell line 
while protecting normal mammary cells (SV40) from apoptosis induced by chemothera-
peutical drugs [123]. Another study confirmed the antineoplastic activity of lutein by in-
ducing apoptosis and cell-cycle arrest in MCF-7 and MDA-MB-468 cell lines. The selective 
effect on tumor cells seems to be due to the induction of ROS production, therefore, due 
to its pro-oxidant activity [138]. Mammary tumor growth was inhibited by the intake of 
lutein in female BALB/c mice [107]. An antiproliferative effect was also detected in fuco-
xanthin treatment in MDA-MB-231 cells and xenograft model [139]. Another marine ca-
rotenoid, astaxanthin, repressed cancer stem cell stemness genes and induced apoptosis 
in the SKBR3 cell line, indicating that it might be helpful in the improvement of current 
therapies [140,141]. In addition, lycopene, zeaxanthin, and capsanthin induced apoptosis 
in MDA-MB-231 and seem to be involved in reversing multidrug resistance [142]. Aside 
from those, lycophyll, luteoxanthin, and violaxanthin were also highly effective. How-
ever, lutein, antheraxanthin, and violaxanthin were moderately successful in reversing 
multidrug resistance. 
Metastasis and cell migration can also be inhibited by carotenoids [143]. The migra-
tion of MCF-7 and MDA-MB-231 cell lines was reduced after the treatment with astaxan-
thin [144]. Lutein was also reported to modulate adherin, vimentin, and N-cadherin levels, 
which are epithelial-mesenchymal transition (EMT) associated factors [145]. In addition, 
it inhibited NOTCH signaling pathway which is related to cell invasion and migration 
[146]. Furthermore, several apocarotenoids inhibited migration and EMT associated fac-
tors in BT-549 and MDA-MB-231 [147]. Therefore, carotenoids and apocarotenoids could 
be helpful preventing metastasis in triple negative tumors. However, there is still lack of 
evidence supporting this theory and much work remains to be completed. 
Combination therapy of carotenoids with chemotherapeutic agents show a lot of 
promise. Recently, doxorubicin was combined with β-carotene and lutein to induce oxi-
dative stress-mediated apoptosis in MCF-7 and MDA-MB-231 breast cancer cell lines. The 
pro-oxidant activity selectively affects tumor cells, sparing normal breast epithelial cells 
(MCF10A) [148] (Figure 4). Co-treatment of astaxanthin with the Phase I anticancer drug 
carbendazim showed a synergistic effect on the MCF-7 cell lines [149]. In combination 
with hyperthermia, crocin successfully inhibited the growth of the MDA-MB-468 TNBC 
cell line, whereas MCF-10A normal cells were not affected [150]. In addition, lutein and 
taxanes, such as paclitaxel, demonstrated a synergistic effect on MCF-7 and MDA-MB-468 
cell lines [138]. Zeaxanthin and violaxanthin were capable of enhancing the antiprolifera-
tive effect of epirubicin on MCF-7 cells resistant to anthracycline [151] 




Figure 4. Major differences in cancer and normal cells metabolism. Over a certain ROS threshold, antioxidants present a 
pro-oxidant activity that leads to the apoptosis of malignant cells. Hence, its potential as chemotherapeutic agent. The 
antioxidant activity acts as a chemopreventive under homeostatic levels of ROS in normal cells. 
6.2. Breast Cancer Antitumor Activity of Carotenoids: Clinical Trials 
Most clinical trials start from the premise that high levels of carotenoids in plasma, 
obtained from carotenoid-rich foods, can prevent the development of breast cancer 
[152,153]. Table 1 includes all registered clinical trials which are studying the effect of ca-
rotenoids on breast cancer patients. Recent studies have associated high levels of β-caro-
tene in plasma with lower ER-breast cancer risk [154] and with reduced systemic inflam-
mation and cognitive improvements in breast cancer survivors [155]. It is worth highlight-
ing the results from the trial NCT00000611, which analyzed serum concentrations of ca-
rotenoids, retinol and tocopherols in women to assess a possible association between these 
values and postmenopausal breast cancer risk. They concluded that indeed, high levels of 
α-carotene and β-carotene were inversely associated with the risk of developing breast 
cancer [156], which coincided with other similar studies [152]. Increased levels of carote-
noids in plasma were also associated with less oxidative stress in breast cancer survivors, 
but inflammatory biomarkers were not affected [157]. A correlation between high levels 
of α-carotene and reduced breast cancer risk was found [139,158], which was consistent 
with the results obtained from the Nurse Health study [159] and the Women’s Health 
Initiative [156]. 
Similarly, plasma concentrations of β-carotene and β-cryptoxanthin were inversely 
correlated with breast cancer risk [160]. In another study, plasma total carotenoid concen-
tration was related to a diminished risk of breast cancer recurrence in patients with an 
early-stage diagnosis [161]. However, not all clinical trials agree with these results. Alt-
hough an association between high levels of total plasma carotenoids and reduced oxida-
tive stress was reported in line with previous trials, these authors also concluded that ca-
rotenoids were not able to protect against breast cancer relapse in postmenopausal breast 
cancer survivors [162,163]. 
In general, most clinical trials related to carotenoids and breast cancer target the effect 
of carotenoid-rich food intake on breast cancer survivors [164]. However, as previously 
mentioned, lifestyle is critical in preventing and progressing breast cancers and the levels 
of oxidative stress. In this matter, oxidative stress plays a significant role in cancer devel-
opment and is also deeply involved in depression, affecting how patients deal with their 
pathology [165]. For this reason, a recent clinical trial is assessing the effect of music ther-
apy on different biomarkers of oxidative stress, including carotenoids (NCT04446624). 
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In summary, there is still not enough evidence to validate the potential benefits of 
carotenoids in preventing and treating breast cancer. Most clinical trials agree that a high 
intake of carotenoids may prevent high-risk and aggressive breast cancer, but further 
studies are required to draw a solid conclusion. Furthermore, no clinical trials assessing 
the supplementation of carotenoids in breast cancer patients, and, therefore, there is a 
complete lack of knowledge regarding this topic. Some studies in other types of cancer 
have reported controversial results [166]. Still, the chemopreventive use of carotenoids 
and the chemotherapeutical results in in vitro and in vivo studies encourage deepening 
the potential of carotenoids as part of the treatment of breast cancer patients. 
Table 1. Clinical trials involving carotenoids in breast cancer. 
NCT Number Status 1 Stage Aim Outcome Reference 
NCT03625635 Unknown NA 
Effect of a nutritional inter-
vention on body composi-
tion, metabolism, and anti-
oxidant activity 
Reduced fat mass while 
preserving skeletal muscle 
mass  
[167] 
NCT02067481 Completed Phase II 
Effect of diet and physical 
activity in breast cancer 
survivors 
Unknown UP 
NCT00000611 Completed Phase III 
Effect on higher fruit and 
vegetable intake on BC pa-
tients 
High levels of plasma ca-
rotenoids associated with 
less BC risk 
[156] 
NCT02109068 Completed Phase III Effect of weight loss in BC survivors Unknown UP 
NCT02110641 Active, no re-cruiting NA 
Effect of weight loss in BC 
survivors Unknown [168] 
NCT04374747 Recruiting NA 
Effect of fruit and vegetable 
intake to reduce BC risk in 
lactating women 
Not measured [169] 
NCT04446624 Completed NA 
Effect of music therapy in 
oxidative stress markers, 
such as carotenoids 
Unknown UP 
NCT00120016 Completed NA Impact of a Mediterranean 
diet on BC risk 
Plasma carotenoids in-
crease with fruit and vege-
table intake 
[170] 
1 Data obtained from ClinicalTrials.gov on 30th September 2021; BC: breast cancer NA: not applicable; UP: unpublished. 
7. Rare Carotenoids from Halophilic Microorganisms: The Future of Biomedicine? 
Bacterioruberin from Haloarchaea 
Haloarchaea have been in the spotlight during the last years due to their ability to 
synthesize compounds of high biotechnological interest, such as bioplastics, thermophilic 
enzymes, and a particular type of carotenoid [12]. 
Haloarchaea synthesize mainly a rare C50 carotenoid called bacterioruberin (BR) and 
its derivatives: bisanhydrobacterioruberin (BABR), monoanhydrobacterioruberin 
(MABR), and 2-isopentenyl-3,4-dehydrorhodopin (IDR) [171–174]. Other derivatives have 
been detected at lower concentrations, such as haloxanthin and 3,4-dehydromonoanhy-
drobacterioruberin; and depending on the haloarchaeal species, such as 3,4-epoxymono-
anhydrobacterioruberin, which has only been described in Haloferax volcanii carotenoid 
extracts [175]. Although β-carotene, lycopene, and phytoene have also been identified in 
haloarchaeal extracts, they are present at low concentrations [171,176]. BR, which is the 
most abundant, presents an interesting chemical structure since its hydrocarbon chain is 
particularly long, with 50 carbon units (Figure 5). Furthermore, it possesses 13 conjugated 
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double bonds in an all-trans conformation. This together with the 4 hydroxyl groups that 
arise from the terminal ends, provide this carotenoid with a higher scavenging potential 
than their C40 counterparts, lycopene, and β-carotene. 
 
Figure 5. Chemical structure of the haloarchaeal carotenoid bacterioruberin. 
A recent study using Haloferax mediterranei describes how BR counteracts the oxida-
tive stress generated by high concentrations of the oxidant hydrogen peroxide. BR suc-
cessfully neutralized hydrogen peroxide, confirming that cells use this carotenoid to keep 
the oxidative balance and that this compound is indeed very efficient against ROS [176]. 
This distinct chemical structure has awakened the interest of many researchers during the 
last years due to the potential biotechnological and biomedical applications that could 
have [12]. Unfortunately, there is still scarce information about its antiproliferative activ-
ity. However, recent studies have reported that BR could selectively inhibit cell growth in 
cell lines from different cancer types, including breast cancer (MCF-7) BR induced more 
substantial caspase-mediated apoptosis than that of the chemotherapeutical agent, 5-
fluorouracil (5-FU) and showed a higher selectivity index than 5-FU. In addition, BR was 
a more potent suppressor of matrix metalloprotease 9 (MMP-9) [177]. MMP-9 is one of the 
key proteases involved in many cancer processes, such as angiogenesis, invasion, and me-
tastasis [178]. However, the nature of the mechanism involved is not currently clear, and 
therefore, much work remains to be completed. In addition, it is still unknown if it will 
also exert pro-oxidant activity and under what conditions. However, the successful results 
obtained in other biomedical areas, such as cryopreservation [179] and anti-viral activity 
[177] invite us to explore what BR could offer to breast cancer prevention and treatment. 
8. Controversy and Setbacks Observed 
The fact that the same molecule can exhibit antioxidant and pro-oxidant activity has 
been subject to controversy and has questioned the efficacy of these compounds in the 
treatment of tumors [118]. Another debatable point is that no consensus in the doses 
should be administered in clinical trials. Therefore, it is complicated to make comparisons 
and draw conclusions. It is also worth mentioning that endogenous factors, such as the 
genetic variability in antioxidant enzymes in each patient, may compromise the efficacy 
of these compounds [180]. 
Breast cancer is a very heterogeneous malignant neoplasia [181] whose different sub-
types may differ in the levels of oxidative stress. The redox status of each subtype should 
be characterized so that the use of antioxidants, such as carotenoids, in the treatment of 
breast cancer can be refined. Each result contributes to a better understanding of the role 
of carotenoids in breast cancer patients. 
However, most studies concur that consuming a collection of carotenoids is a better 
anticancer strategy than a high intake of one specific carotenoid. Nowadays, there is par-
ticular controversy regarding using antioxidants due to the complexity in recognizing 
their positive or negative effects on patient outcomes. In addition, most clinical trials have 
focused on the supplementation of carotenoids to diminish adverse chemotherapy effects 
or as chemopreventive compounds [154,164]. Although many in vitro and in vivo assays 
focus on the antitumor effect of carotenoids, trials focused on carotenoids as an actual 
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treatment for breast cancer are nonexistent. Therefore, it is hard to confirm if carotenoids 
could be helpful in the fight against this common pathology among women. One of the 
potential changes in the current approach on using carotenoids in clinical trials could be 
intravenous administration instead of supplementation to reach a higher plasmatic con-
centration. What is clear is that further research on this topic is required to make a clear 
conclusion. 
9. Conclusions 
In closing, for many years, natural compounds have been useful in preventing many 
diseases. Some of those, such as taxane, was part of the development of current chemo-
therapeutical drugs [182]. To date, almost half of current anticancer drugs are derivatives 
of natural compounds or their mimics [183]. Now it is time to evaluate if carotenoids could 
rise from chemopreventive to chemotherapeutical agents. For this reason, preclinical re-
search should be encouraged to elucidate what is the exact role of carotenoids in the onset 
and progression of breast cancer. 
Moreover, the precise conditions under which a carotenoid shows antioxidant or pro-
oxidant activity must be determined. Combined therapy studies are also key to establish 
any positive or negative interaction with current chemotherapy protocols. Finally, novel 
carotenoids, such as bacterioruberin, need to be investigated to deepen their potential 
value in treating malignant neoplasias. 
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